Exhibit 10.7
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
July 20, 2005
Jack Dean
President, U.S. Science & Medical
Affairs
Aventis Pharmaceuticals Inc., a member of
the sanofi-aventis Group
1041 Route 202-206
Bridgewater, NJ 08807
Dear Jack:
Under the terms of the
Collaboration and License Agreement dated June
22, 2000 (as amended) between Millennium
Pharmaceuticals, Inc. ("Millennium")
and Aventis Pharmaceuticals Inc.
("Aventis"), (as so amended, the "Collaboration
Agreement"), the Research Program Term is
scheduled to end on July 21, 2005.
Millennium and Aventis are currently
discussing continuing certain aspects of
the Research Program beyond July 21, 2005,
and making certain other changes to
the Collaboration Agreement, but the
Parties anticipate that they will not be
able to complete those discussions before
July 21, 2005. Therefore, Millennium
and Aventis wish to extend the Research
Program Term in accordance with the
terms of this letter agreement to
facilitate the completion of those ongoing
discussions. All capitalized terms used in
this letter agreement and not
otherwise defined in this letter agreement
have the meanings assigned them in
the Collaboration Agreement.
Millennium and Aventis
agree that the Research Program Term will be
extended for the following purposes
only:
1. To permit [**] the Program Targets [**];
2. To permit [**] Research Targets; and
3. For the Program Target [**].
The Rese
